iCAD, Inc. (NASDAQ:ICAD) Short Interest Update

iCAD, Inc. (NASDAQ:ICAD) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 231,100 shares, a decrease of 23.1% from the February 13th total of 300,600 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average trading volume of 444,700 shares, the short-interest ratio is currently 0.5 days.

Institutional Investors Weigh In On iCAD

A number of institutional investors have recently modified their holdings of the business. First Eagle Investment Management LLC grew its position in shares of iCAD by 6.1% during the 4th quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock valued at $1,311,000 after acquiring an additional 41,000 shares during the period. Geode Capital Management LLC lifted its stake in iCAD by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company’s stock worth $506,000 after purchasing an additional 17,059 shares in the last quarter. Perritt Capital Management Inc lifted its stake in iCAD by 1.9% in the 4th quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company’s stock worth $346,000 after purchasing an additional 3,600 shares in the last quarter. Summit Trail Advisors LLC acquired a new stake in shares of iCAD during the 4th quarter worth approximately $214,000. Finally, Granahan Investment Management LLC acquired a new stake in shares of iCAD during the 4th quarter worth approximately $96,000. 24.61% of the stock is currently owned by institutional investors and hedge funds.

iCAD Trading Down 0.4 %

ICAD traded down $0.01 during midday trading on Tuesday, hitting $2.32. 199,432 shares of the company were exchanged, compared to its average volume of 247,663. The company’s 50 day simple moving average is $2.63 and its 200 day simple moving average is $2.05. The firm has a market capitalization of $61.57 million, a price-to-earnings ratio of -17.85 and a beta of 1.95. iCAD has a 1-year low of $1.18 and a 1-year high of $3.78.

Analysts Set New Price Targets

Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, February 20th.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.